Patents by Inventor Dan Littman
Dan Littman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10561666Abstract: Amido compounds are disclosed that have a formula represented by the following: and wherein n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.Type: GrantFiled: November 14, 2016Date of Patent: February 18, 2020Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NEW YORK UNIVERSITYInventors: Dan Littman, Jun R. Huh, Ruili Huang, Wenwei Huang, Erika Elaine Englund
-
Patent number: 9765063Abstract: Amido compounds are disclosed that have a formula represented by the following: and wherein Cy1, Cy2, n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.Type: GrantFiled: September 10, 2012Date of Patent: September 19, 2017Assignees: New York University, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Dan Littman, Jun R. Huh, Ruili Huang, Wenwei Huang, Erika E. Englund
-
Publication number: 20170159057Abstract: The present invention relates to expression of ROR?t in cells and tissues and the effect of expression of this gene on proliferation of specific immune cells and in promotion of immune cell aggregates and in induction of IL17 producing cells. Furthermore, the invention relates to methods and agents that may decrease function of the gene product (the protein) or expression of this gene in individuals experiencing an inflammatory condition, an autoimmune disease or a food allergy, or any other condition whereby it is desirable to inhibit an immune response. In addition, methods and agents useful for enhancing the function of ROR?t with agonists or expression of this gene are also considered for use whereby it is desirable to increase immunity to a pathogen or tumor cell, for example, for use in conjunction with a vaccine. Screening methods for identifying novel modulators (antagonists and agonists) of ROR?t are also disclosed.Type: ApplicationFiled: November 22, 2016Publication date: June 8, 2017Inventors: Dan Littman, Gerard Eberl, Liang Zhou, Ivaylo Ivanov
-
Publication number: 20170065606Abstract: Amido compounds are disclosed that have a formula represented by the following: and wherein n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.Type: ApplicationFiled: November 14, 2016Publication date: March 9, 2017Inventors: Dan LITTMAN, Jun R. HUH, Ruili HUANG, Wenwei HUANG, Erika Elaine ENGLUND
-
Patent number: 9492439Abstract: Amido compounds are disclosed that have a formula represented by the following: and wherein n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.Type: GrantFiled: March 11, 2011Date of Patent: November 15, 2016Assignees: New York University, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Dan Littman, Jun R. Huh, Wenwei Huang, Ruili Huang, Erika Elaine Englund
-
Patent number: 9358281Abstract: The present invention relates to enhancing, modulating or stimulating the innate immune response to HIV-1 and other viral pathogens and to the modulation and application of immune modulators and peptides for HIV-1 or other pathogen vaccines. The invention provides methods and means to activate an innate response to HIV-1 utilizing or via the HIV capsid protein or peptide, including modulating the binding of cyclophilin A to HIV capsid protein and modulating the ability of HIV to activate the major innate transcription factor IRF3 and interferon. Methods and assays are provided for screening for compounds, agents, or peptides capable of enhancing or activating innate immune response, particularly to HIV-1.Type: GrantFiled: October 12, 2010Date of Patent: June 7, 2016Assignee: New York UniversityInventors: Dan Littman, Nicolas Manel
-
Publication number: 20150224152Abstract: The present invention relates to methods for treating or reducing the risk of or preventing diseases caused by or associated with pathogenic bacteria. More particularly, the present invention relates to methods for treating or reducing the risk of or preventing diseases caused by or associated with pathogenic bacteria of the gastrointestinal (GI) tract. The present invention further relates to methods for promoting pathways induced by commensal bacteria of the GI tract that lead to Th17 differentiation, which in turn leads to localized and systemic accumulation of Th17 cells. Compositions and medicaments are also described herein that are used alleviate and/or prevent symptoms associated with diseases caused by or associated with pathogenic bacteria. Accordingly, the compositions, medicaments and methods described herein may be used to address the needs of patients or subjects that would benefit from increased Th17 cell differentiation.Type: ApplicationFiled: October 29, 2014Publication date: August 13, 2015Inventors: Dan Littman, Ivaylo Ivanov, Eoin Brodie, Yoshinori Umesaki, Kenya Honda
-
Patent number: 9101600Abstract: Heterocyclic compounds, and pharmaceutical compositions thereof, are disclosed as ROR?t modulators that have a formula represented by the following: and wherein n1, n2, R1, R2, R3, and R4 are as described herein. These compounds may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.Type: GrantFiled: March 11, 2011Date of Patent: August 11, 2015Assignees: New York University, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Dan Littman, Jun R. Huh, Wenwei Huang, Ruili Huang
-
Publication number: 20150218563Abstract: The present invention relates to expression of ROR?t in cells and tissues and the effect of expression of this gene on proliferation of specific immune cells and in promotion of immune cell aggregates and in induction of IL17 producing cells. Furthermore, the invention relates to methods and agents that may decrease function of the gene product (the protein) or expression of this gene in individuals experiencing an inflammatory condition, an autoimmune disease or a food allergy, or any other condition whereby it is desirable to inhibit an immune response. In addition, methods and agents useful for enhancing the function of ROR?t with agonists or expression of this gene are also considered for use whereby it is desirable to increase immunity to a pathogen or tumor cell, for example, for use in conjunction with a vaccine. Screening methods for identifying novel modulators (antagonists and agonists) of ROR?t are also disclosed.Type: ApplicationFiled: January 5, 2015Publication date: August 6, 2015Inventors: Dan Littman, Gerard Eberl, Liang Zhou, Ivaylo Ivanov
-
Publication number: 20150057278Abstract: Amido compounds are disclosed that have a formula represented by the following: and wherein Cy1, Cy2, n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.Type: ApplicationFiled: September 10, 2012Publication date: February 26, 2015Inventors: Dan Littman, Jun R. Huh, Ruili Huang, Wenwei Huang, Erika E. Englund
-
Publication number: 20140121201Abstract: Screening assays and methods of using same for screening to identify modulator agents or compounds that affect Th17 cell specification are described herein. Pharmaceutical compositions comprising agents or compounds that modulate Th17 cell specification are also encompassed. Methods for modulating Th17 cell specification using agents identified using assays described herein in pharmaceutical compositions are also envisioned. Such pharmaceutical compositions are useful for treating inflammatory conditions and autoimmune diseases associated with Th17 cell mediated pathology.Type: ApplicationFiled: September 24, 2013Publication date: May 1, 2014Inventors: Dan Littman, Maria Ciofani, Richard A. Bonneau, JR.
-
Publication number: 20130085162Abstract: Amido compounds are disclosed that have a formula represented by the following: and wherein n1, n2, R1a, R1b, R2, R3, R4, R5, and R6 are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.Type: ApplicationFiled: March 11, 2011Publication date: April 4, 2013Inventors: Dan Littman, Jun R. Huh, Wenwei Huang, Ruili Huang, Erika Elaine Englund
-
Publication number: 20130065842Abstract: Heterocyclic compounds, and pharmaceutical compositions thereof, are disclosed as ROR?t modulators that have a formula represented by the following: and wherein n1, n2, R1, R2, R3, and R4 are as described herein. These compounds may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.Type: ApplicationFiled: March 11, 2011Publication date: March 14, 2013Inventors: Dan Littman, Jun R. Huh, Wenwei Huang, Ruili Huang
-
Publication number: 20120276149Abstract: The present invention relates to methods for treating or reducing the risk of or preventing diseases caused by or associated with pathogenic bacteria. More particularly, the present invention relates to methods for treating or reducing the risk of or preventing diseases caused by or associated with pathogenic bacteria of the gastrointestinal (GI) tract. The present invention further relates to methods for promoting pathways induced by commensal bacteria of the GI tract that lead to Th17 differentiation, which in turn leads to localized and systemic accumulation of Th17 cells. Compositions and medicaments are also described herein that are used alleviate and/or prevent symptoms associated with diseases caused by or associated with pathogenic bacteria. Accordingly, the compositions, medicaments and methods described herein may be used to address the needs of patients or subjects that would benefit from increased Th17 cell differentiation.Type: ApplicationFiled: October 15, 2010Publication date: November 1, 2012Inventors: Dan Littman, Ivaylo Ivanov, Eoin Brodie, Yoshinori Umesaki, Kenya Honda
-
Publication number: 20110159025Abstract: The present invention relates to enhancing, modulating or stimulating the innate immune response to HIV-1 and other viral pathogens and to the modulation and application of immune modulators and peptides for HIV-1 or other pathogen vaccines. The invention provides methods and means to activate an innate response to HIV-1 utilizing or via the HIV capsid protein or peptide, including modulating the binding of cyclophilin A to HIV capsid protein and modulating the ability of HIV to activate the major innate transcription factor IRF3 and interferon. Methods and assays are provided for screening for compounds, agents, or peptides capable of enhancing or activating innate immune response, particularly to HIV-1.Type: ApplicationFiled: October 12, 2010Publication date: June 30, 2011Inventors: Dan Littman, Nicolas Manel
-
Publication number: 20070154487Abstract: The present invention relates to expression of ROR?t in cells and tissues and the effect of expression of this gene on proliferation of specific immune cells and in promotion of immune cell aggregates and in induction of IL17 producing cells. Furthermore, the invention relates to methods and agents that may decrease function of the gene product (the protein) or expression of this gene in individuals experiencing an inflammatory condition, an autoimmune disease or a food allergy, or any other condition whereby it is desirable to inhibit an immune response. In addition, methods and agents useful for enhancing the function of ROR?t with agonists or expression of this gene are also considered for use whereby it is desirable to increase immunity to a pathogen or tumor cell, for example, for use in conjunction with a vaccine. Screening methods for identifying novel modulators (antagonists and agonists) of ROR?t are also disclosed.Type: ApplicationFiled: September 20, 2006Publication date: July 5, 2007Inventors: Dan Littman, Gerard Eberl, Liang Zhou, Ivaylo Ivanov
-
Patent number: 5670324Abstract: The present invention provides chimeric proteins containing extracellular and transmembrane domains of CD4 and protein tyrosine kinases of the src family. Also provided are DNA molecules encoding the proteins of the present invention and cells containing such DNA molecules. The proteins and cells of the present invention may be employed in methods for identifying drugs that block T cell activation and for identifying low level self-antigens.Type: GrantFiled: June 2, 1995Date of Patent: September 23, 1997Assignee: The Regents of the University of CaliforniaInventors: Dan Littman, Hua Xu
-
Patent number: 5504000Abstract: The present invention provides chimeric proteins containing extracellular and transmembrane domains of CD4 and protein tyrosine kinases of the src family. Also provided are DNA molecules encoding the proteins of the present invention and cells containing such DNA molecules. The proteins and cells of the present invention may be employed in methods for identifying drugs that block T cell activation and for identifying low level self-antigens.Type: GrantFiled: June 2, 1995Date of Patent: April 2, 1996Assignee: Regents of the University of CaliforniaInventors: Dan Littman, Hua Xu
-
Patent number: 5439819Abstract: The present invention provides chimeric proteins containing extracellular and transmembrane domains of CD4 and protein tyrosine kinases of the src family. Also provided are DNA molecules encoding the proteins of the present invention and cells containing such DNA molecules. The proteins and cells of the present invention may be employed in methods for identifying drugs that block T cell activation and for identifying low level self-antigens.Type: GrantFiled: August 27, 1993Date of Patent: August 8, 1995Assignee: The Regents of the University of CaliforniaInventors: Dan Littman, Hua Xu